PapersFlow Research Brief
Transplantation: Methods and Outcomes
Research Guide
What is Transplantation: Methods and Outcomes?
Transplantation: Methods and Outcomes refers to the surgical procedures for transferring organs such as lungs and hearts from donors to recipients, along with the evaluation of post-transplant survival rates, rejection mechanisms like allograft vasculopathy and bronchiolitis obliterans syndrome, and interventions including ex vivo perfusion and immunosuppressive therapy.
This field encompasses 79,142 published works on organ transplantation advancements. Key areas include lung and heart transplants, rejection processes such as allograft vasculopathy and bronchiolitis obliterans syndrome, ex vivo perfusion techniques, primary graft dysfunction, and donor selection criteria. Immunosuppressive therapy directly influences post-transplant outcomes across these procedures.
Topic Hierarchy
Research Sub-Topics
Lung Transplant Rejection Mechanisms
This sub-topic examines immunological processes leading to acute and chronic rejection in lung transplantation, including bronchiolitis obliterans syndrome and antibody-mediated rejection. Researchers investigate diagnostic biomarkers, histopathological grading, and therapeutic interventions to mitigate rejection.
Heart Transplant Allograft Vasculopathy
This sub-topic focuses on the pathogenesis, risk factors, and progression of coronary allograft vasculopathy following heart transplantation. Studies explore imaging techniques, endothelial dysfunction, and novel immunosuppressive strategies to prevent this leading cause of late graft failure.
Ex Vivo Lung Perfusion
This sub-topic covers techniques for ex vivo lung perfusion to assess and recondition marginal donor lungs prior to transplantation. Researchers study perfusion protocols, therapeutic interventions during perfusion, and clinical outcomes of transplanted perfused lungs.
Primary Graft Dysfunction in Lung Transplantation
This sub-topic investigates the incidence, pathophysiology, and risk factors of primary graft dysfunction, a severe early complication after lung transplantation. Research includes biomarkers, preventive strategies, and impact on short-term outcomes.
Immunosuppressive Therapy Optimization
This sub-topic addresses regimens, side effects, and personalized approaches to immunosuppressive therapy in solid organ transplantation. Researchers analyze drug interactions, minimization protocols, and long-term effects on infection and malignancy risks.
Why It Matters
Transplantation methods enable life-saving interventions for end-stage organ failure, with heart-lung transplantation achieving an average survival rate of 50%, as detailed in "Heart-Lung Transplantation" by Griffith et al. (2016), which highlights donor criteria and rejection management. Peak exercise oxygen consumption measurements optimize cardiac transplantation timing in ambulatory heart failure patients, as shown in "Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure" by Mancini et al. (1991), identifying low-risk patients who can safely defer surgery. Standardized nomenclature revisions, such as in "Revision of the 1996 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Lung Rejection" by Stewart et al. (2007) and "Revision of the 1990 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Heart Rejection" by Stewart et al. (2005), improve diagnostic consistency for rejection, enhancing outcomes in lung and heart transplants.
Reading Guide
Where to Start
"Heart-Lung Transplantation" by Griffith et al. (2016) provides an accessible overview of survival rates, donor criteria, and rejection challenges, making it ideal for initial reading on combined transplant methods and outcomes.
Key Papers Explained
"Revision of the 1996 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Lung Rejection" by Stewart et al. (2007) and "Revision of the 1990 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Heart Rejection" by Stewart et al. (2005) establish parallel diagnostic standards that underpin rejection assessment in both lung and heart contexts. "J Heart Lung Transplant 2021;40(4)" by Dinh et al. (2021), the most-cited paper with 6869 citations, likely builds on these by applying updated criteria to contemporary outcomes. "Ischemia and reperfusion—from mechanism to translation" by Eltzschig and Eckle (2011) connects mechanistic insights to these clinical standards, informing preservation methods.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Standardized rejection grading from Stewart et al. (2007, 2005) remains central, with "J Heart Lung Transplant 2021;40(4)" by Dinh et al. (2021) representing the highest citation impact at 6869. No recent preprints or news indicate ongoing refinements in ex vivo perfusion or donor criteria.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | J Heart Lung Transplant 2021;40(4). | 2021 | The Journal of Heart a... | 6.9K | ✓ |
| 2 | Guidelines for the diagnosis and treatment of pulmonary hypert... | 2009 | European Heart Journal | 3.8K | ✓ |
| 3 | Ischemia and reperfusion—from mechanism to translation | 2011 | Nature Medicine | 3.2K | ✓ |
| 4 | Revision of the 1996 Working Formulation for the Standardizati... | 2007 | The Journal of Heart a... | 2.4K | ✕ |
| 5 | Heart-Lung Transplantation | 2016 | — | 2.2K | ✓ |
| 6 | Repair of Infarcted Myocardium by Autologous Intracoronary Mon... | 2002 | Circulation | 2.1K | ✕ |
| 7 | The Natural History of Chronic Allograft Nephropathy | 2003 | New England Journal of... | 1.9K | ✓ |
| 8 | Idiopathic Pulmonary Fibrosis | 2018 | New England Journal of... | 1.9K | ✕ |
| 9 | Value of peak exercise oxygen consumption for optimal timing o... | 1991 | Circulation | 1.8K | ✓ |
| 10 | Revision of the 1990 Working Formulation for the Standardizati... | 2005 | The Journal of Heart a... | 1.7K | ✕ |
Frequently Asked Questions
What standardization exists for diagnosing lung transplant rejection?
"Revision of the 1996 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Lung Rejection" by Stewart et al. (2007) provides updated criteria for classifying lung rejection pathology. This revision ensures consistent nomenclature across biopsies. It has received 2413 citations for its impact on clinical practice.
How is heart transplant rejection nomenclature defined?
"Revision of the 1990 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Heart Rejection" by Stewart et al. (2005) revises grading for heart biopsy rejection. The system categorizes acute cellular and antibody-mediated rejection. It is cited 1740 times for standardizing post-heart transplant diagnostics.
What is the survival rate for heart-lung transplantation?
"Heart-Lung Transplantation" by Griffith et al. (2016) reports an average survival rate of 50% for cardiopulmonary transplantation. This falls below isolated cardiac transplant outcomes due to factors like donor criteria and rejection. Advances in these areas aim to improve results.
How does peak VO2 guide cardiac transplantation timing?
"Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure" by Mancini et al. (1991) demonstrates that peak VO2 during exercise identifies low-risk heart failure patients. Those with higher VO2 can defer transplantation safely. This approach optimizes resource allocation.
What role does ischemia-reperfusion play in transplant outcomes?
"Ischemia and reperfusion—from mechanism to translation" by Eltzschig and Eckle (2011) explains ischemia-reperfusion injury mechanisms in transplantation. It translates basic findings to clinical strategies reducing organ damage. The paper has 3227 citations for bridging research to practice.
What are key aspects of chronic allograft nephropathy?
"The Natural History of Chronic Allograft Nephropathy" by Nankivell et al. (2003) describes it as cumulative nephron damage from immunologic and nonimmunologic causes over time. This affects long-term kidney transplant outcomes. Monitoring helps mitigate progression.
Open Research Questions
- ? How can ex vivo perfusion techniques be optimized to reduce primary graft dysfunction in lung transplants?
- ? What donor selection criteria best predict outcomes in heart-lung transplantation to exceed the current 50% survival rate?
- ? Which immunosuppressive therapies most effectively prevent bronchiolitis obliterans syndrome without increasing infection risks?
- ? How do mechanisms of allograft vasculopathy differ between heart and lung transplants, and what targeted interventions exist?
- ? What metrics beyond peak VO2 improve timing decisions for cardiac transplantation in ambulatory patients?
Recent Trends
The field includes 79,142 works with growth data unavailable, reflecting sustained focus on lung and heart transplants. "J Heart Lung Transplant 2021;40(4)" by Dinh et al. leads citations at 6869, emphasizing current journal priorities in heart-lung transplantation outcomes.
2021Research Transplantation: Methods and Outcomes with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Transplantation: Methods and Outcomes with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers